206 related articles for article (PubMed ID: 20679962)
1. Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil.
Gensburger O; Van Schaik RH; Picard N; Le Meur Y; Rousseau A; Woillard JB; Van Gelder T; Marquet P
Pharmacogenet Genomics; 2010 Sep; 20(9):537-43. PubMed ID: 20679962
[TBL] [Abstract][Full Text] [Related]
2. Inosine monophosphate dehydrogenase polymorphisms and renal allograft outcome.
Shah S; Harwood SM; Döhler B; Opelz G; Yaqoob MM
Transplantation; 2012 Sep; 94(5):486-91. PubMed ID: 22960765
[TBL] [Abstract][Full Text] [Related]
3. Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal transplantation.
Kagaya H; Miura M; Saito M; Habuchi T; Satoh S
Basic Clin Pharmacol Toxicol; 2010 Aug; 107(2):631-6. PubMed ID: 20136638
[TBL] [Abstract][Full Text] [Related]
4. Malnutrition Risk in Kidney Recipients Treated With Mycophenolate Mofetil Is Associated With IMPDH1 rs2278294 Polymorphism.
Pazik J; Lewandowski Z; Nowacka Cieciura E; Ołdak M; Podgórska M; Sadowska A; Dęborska Materkowska D; Durlik M
Transplant Proc; 2018; 50(6):1794-1797. PubMed ID: 30056902
[TBL] [Abstract][Full Text] [Related]
5. Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy.
Chiarelli LR; Molinaro M; Libetta C; Tinelli C; Cosmai L; Valentini G; Dal Canton A; Regazzi M
Br J Clin Pharmacol; 2010 Jan; 69(1):38-50. PubMed ID: 20078611
[TBL] [Abstract][Full Text] [Related]
6. Effect of mycophenolic acid on inosine monophosphate dehydrogenase (IMPDH) activity in liver transplant patients.
Neuberger M; Sommerer C; Böhnisch S; Metzendorf N; Mehrabi A; Stremmel W; Gotthardt D; Zeier M; Weiss KH; Rupp C
Clin Res Hepatol Gastroenterol; 2020 Sep; 44(4):543-550. PubMed ID: 31924555
[TBL] [Abstract][Full Text] [Related]
7. Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism.
Sombogaard F; van Schaik RH; Mathot RA; Budde K; van der Werf M; Vulto AG; Weimar W; Glander P; Essioux L; van Gelder T
Pharmacogenet Genomics; 2009 Aug; 19(8):626-34. PubMed ID: 19617864
[TBL] [Abstract][Full Text] [Related]
8. The combination of exposure to Tacrolimus, mycophenolic acid, Inosine 5'-Monophosphate Dehydrogenase activity and inhibition in the first week define early histological outcomes in renal transplant recipients.
Thanukrishnan H; Venkataramanan R; Mehta RB; Jorgensen D; Sood P
Clin Transplant; 2022 Dec; 36(12):e14830. PubMed ID: 36177865
[TBL] [Abstract][Full Text] [Related]
9. An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients.
Vannozzi F; Filipponi F; Di Paolo A; Danesi R; Urbani L; Bocci G; Catalano G; De Simone P; Mosca F; Del Tacca M
Transplant Proc; 2004 Nov; 36(9):2787-90. PubMed ID: 15621150
[TBL] [Abstract][Full Text] [Related]
10. Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment.
Vethe NT; Mandla R; Line PD; Midtvedt K; Hartmann A; Bergan S
Scand J Clin Lab Invest; 2006; 66(1):31-44. PubMed ID: 16464785
[TBL] [Abstract][Full Text] [Related]
11. Inosine 5'-Monophosphate Dehydrogenase Activity for the Longitudinal Monitoring of Mycophenolic Acid Treatment in Kidney Allograft Recipients.
Glander P; Waiser J; Hambach P; Bachmann F; Budde K; Eckardt KU; Friedersdorff F; Gaedeke J; Kron S; Lorkowski C; Mai M; Neumayer HH; Peters R; Rudolph B; Schmidt D; Wu K; Liefeldt L
Transplantation; 2021 Apr; 105(4):916-927. PubMed ID: 32496356
[TBL] [Abstract][Full Text] [Related]
12. IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients.
Wang J; Yang JW; Zeevi A; Webber SA; Girnita DM; Selby R; Fu J; Shah T; Pravica V; Hutchinson IV; Burckart GJ
Clin Pharmacol Ther; 2008 May; 83(5):711-7. PubMed ID: 17851563
[TBL] [Abstract][Full Text] [Related]
13. An inosine 5'-monophosphate dehydrogenase 2 single-nucleotide polymorphism impairs the effect of mycophenolic acid.
Winnicki W; Weigel G; Sunder-Plassmann G; Bajari T; Winter B; Herkner H; Sengoelge G
Pharmacogenomics J; 2010 Feb; 10(1):70-6. PubMed ID: 19770842
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update.
Staatz CE; Tett SE
Arch Toxicol; 2014 Jul; 88(7):1351-89. PubMed ID: 24792322
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolate pharmacokinetics and inosine monophosphate dehydrogenase activity in liver transplant recipients with an emphasis on therapeutic drug monitoring.
Reine PA; Vethe NT; Kongsgaard UE; Andersen AM; Line PD; Ali AM; Bergan S
Scand J Clin Lab Invest; 2013 Mar; 73(2):117-24. PubMed ID: 23281843
[TBL] [Abstract][Full Text] [Related]
16. Expression of inosine monophosphate dehydrogenase type I and type II after mycophenolate mofetil treatment: a 2-year follow-up in kidney transplantation.
Sanquer S; Maison P; Tomkiewicz C; Macquin-Mavier I; Legendre C; Barouki R; Lang P
Clin Pharmacol Ther; 2008 Feb; 83(2):328-35. PubMed ID: 17713475
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms in IMPDH2, UGT2B7, and CES2 genes influence the risk of graft rejection in kidney transplant recipients taking mycophenolate mofetil.
Cilião HL; Camargo-Godoy RBO; Souza MF; Zanuto A; Delfino VDA; Cólus IMS
Mutat Res Genet Toxicol Environ Mutagen; 2018 Dec; 836(Pt B):97-102. PubMed ID: 30442353
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients.
Sommerer C; Müller-Krebs S; Schaier M; Glander P; Budde K; Schwenger V; Mikus G; Zeier M
Br J Clin Pharmacol; 2010 Apr; 69(4):346-57. PubMed ID: 20406219
[TBL] [Abstract][Full Text] [Related]
19. Inosine monophosphate dehydrogenase activity and mycophenolate pharmacokinetics in children with nephrotic syndrome treated with mycophenolate mofetil.
Sobiak J; Resztak M; Zachwieja J; Ostalska-Nowicka D
Clin Exp Pharmacol Physiol; 2022 Nov; 49(11):1197-1208. PubMed ID: 35877984
[TBL] [Abstract][Full Text] [Related]
20. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients.
Glander P; Hambach P; Braun KP; Fritsche L; Waiser J; Mai I; Neumayer HH; Budde K
Int J Clin Pharmacol Ther; 2003 Oct; 41(10):470-6. PubMed ID: 14703953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]